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1. Introduction {#mol22015961129-sec-sec1}
===============

Malignant peripheral nerve sheath tumour (MPNST) is a rare and aggressive soft tissue cancer of neuroectodermal origin ([Nielsen et al., 2013](#mol22015961129-bib-0035){ref-type="ref"}; [Zhu and Parada, 2002](#mol22015961129-bib-0061){ref-type="ref"}). The disease typically strikes patients in early adulthood, and nearly half of the patients are diagnosed with the hereditary genetic disorder of von Recklinghausen, neurofibromatosis type 1 (NF1). NF1 is caused by germline mutations in the tumour suppressor gene *NF1* which leads to increased signalling through the RAS/ERK pathway, and inactivating mutations in the *NF1* gene is found in both sporadic and NF1‐associated MPNST ([Bottillo et al., 2009](#mol22015961129-bib-0004){ref-type="ref"}; [Lee et al., 2014](#mol22015961129-bib-0024){ref-type="ref"}). The 5‐year overall survival after an MPNST diagnosis lies in the range between 20 and 50% ([Kolberg et al., 2013](#mol22015961129-bib-0022){ref-type="ref"}), and there are currently no standardized treatment protocols other than surgery. Due to the rareness of the disease, systematic clinical trials to obtain robust and statistically significant information about treatment response among MPNST patients are difficult to perform, and so far, no conventional chemotherapeutic drugs have shown consistent improvement of disease outcome ([Katz et al., 2009](#mol22015961129-bib-0017){ref-type="ref"}).

In addition to *NF1* inactivation, alterations of several other genes and their encoded products have been implicated in the tumourigenesis of MPNST ([Carroll, 2012](#mol22015961129-bib-0007){ref-type="ref"}). Concurrent inactivation of the genes *TP53* and *NF1* in mouse models results in the formation of tumours similar to the MPNSTs seen in humans ([Cichowski et al., 1999](#mol22015961129-bib-0008){ref-type="ref"}; [Vogel et al., 1999](#mol22015961129-bib-0054){ref-type="ref"}). The frequency of *TP53* point mutations in human MPNSTs is debated ([Nigro et al., 1989](#mol22015961129-bib-0029){ref-type="ref"}; [Lothe et al., 2001](#mol22015961129-bib-0036){ref-type="ref"}; [Verdijk et al., 2010](#mol22015961129-bib-0053){ref-type="ref"}), but genomic loss from chromosome arm 17p, including *TP53*, is common ([Brekke et al., 2010](#mol22015961129-bib-0006){ref-type="ref"}). Cell cycle genes have been found implicated in MPNST, in particular frequent deletions and rearrangements of *CDKN2A* ([Berner et al., 1999](#mol22015961129-bib-0003){ref-type="ref"}; [Nielsen et al., 1999](#mol22015961129-bib-0034){ref-type="ref"}). Two recent high throughput seqencing studies of human MPNSTs verified the findings on *NF1*, *TP53*, and *CDKN2A*, but in general they showed that there were very few recurrent mutations in MPNST ([Lee et al., 2014](#mol22015961129-bib-0024){ref-type="ref"}; [Zhang et al., 2014](#mol22015961129-bib-0060){ref-type="ref"}). A striking exception was reported for the two genes *SUZ12* and *EED*, whose gene products are part of the polycomb repressor complex 2 (PRC2). These were found to be frequently lost or mutated in both sporadic and NF1 associated MPNST ([Lee et al., 2014](#mol22015961129-bib-0024){ref-type="ref"}; [Zhang et al., 2014](#mol22015961129-bib-0060){ref-type="ref"}). Inactivation of PRC2 was shown to drive differential gene expression, especially for Ras target genes ([De Raedt et al., 2014](#mol22015961129-bib-0009){ref-type="ref"}).

Microarray based studies of MPNSTs have reported characteristic genome and transcriptome patterns, altered activity of molecular pathways and single gene changes ([Holtkamp et al., 2004](#mol22015961129-bib-0014){ref-type="ref"}; [Miller et al., 2006](#mol22015961129-bib-0033){ref-type="ref"}; [Rahrmann et al., 2013](#mol22015961129-bib-0042){ref-type="ref"}; [Watson et al., 2004](#mol22015961129-bib-0055){ref-type="ref"}; [Yang et al., 2011](#mol22015961129-bib-0058){ref-type="ref"}; [Yu et al., 2011](#mol22015961129-bib-0059){ref-type="ref"}). A number of miRNAs have also been found to be differentially expressed ([Sedani et al., 2012](#mol22015961129-bib-0047){ref-type="ref"}). Typical of the referred studies is the limitation of sample size, and thus, the frequencies of the aberrations identified vary among the studies, and conclusive data often remain unknown. A number of previous studies using FFPE material have analysed protein expression in MPNST, including studies on EGFR and ERBB2 expression ([Holtkamp et al., 2008](#mol22015961129-bib-0013){ref-type="ref"}; [Keizman et al., 2009](#mol22015961129-bib-0018){ref-type="ref"}; [Rahrmann et al., 2014](#mol22015961129-bib-0041){ref-type="ref"}; [Tabone‐Eglinger et al., 2008](#mol22015961129-bib-0052){ref-type="ref"}; [Zou et al., 2009](#mol22015961129-bib-0062){ref-type="ref"}), TP53 ([Brekke et al., 2009](#mol22015961129-bib-0005){ref-type="ref"}; [Yu et al., 2011](#mol22015961129-bib-0059){ref-type="ref"}; [Zou et al., 2009](#mol22015961129-bib-0062){ref-type="ref"}), BIRC5 ([Ghadimi et al., 2012](#mol22015961129-bib-0012){ref-type="ref"}; [Tabone‐Eglinger et al., 2008](#mol22015961129-bib-0052){ref-type="ref"}), TOP2A ([Skotheim et al., 2003](#mol22015961129-bib-0049){ref-type="ref"}), as well as FOXM1, MYC and SOX5 ([Yu et al., 2011](#mol22015961129-bib-0059){ref-type="ref"}). In several of these studies, an association was found between protein expression and prognosis. However, the number of patients included is still a challenge, the end‐points used varies among studies and the stage of the disease at sampling is not always referred, and therefore, the clinical use of these prognostic data remain absent.

MPNSTs often show complex karyotypes, with chromosome 17 as one of the most frequently altered chromosomes ([Brekke et al., 2010](#mol22015961129-bib-0006){ref-type="ref"}; [Lothe et al., 1996](#mol22015961129-bib-0028){ref-type="ref"}; [Mertens et al., 2000](#mol22015961129-bib-0032){ref-type="ref"}; [Schmidt et al., 1999](#mol22015961129-bib-0046){ref-type="ref"}; [Yu et al., 2011](#mol22015961129-bib-0059){ref-type="ref"}). Deletions of chromosome arm 17p and the proximal part of 17q, containing the *TP53* and *NF1* genes, respectively, are frequently observed in both sporadic and NF1‐associated MPNST (Fletcher et al., [1999](#mol22015961129-bib-0011){ref-type="ref"}, [2002](#mol22015961129-bib-0020){ref-type="ref"}, [2002](#mol22015961129-bib-0021){ref-type="ref"}, [1993](#mol22015961129-bib-0025){ref-type="ref"}, [1995](#mol22015961129-bib-0030){ref-type="ref"}, [1990](#mol22015961129-bib-0031){ref-type="ref"}), whereas gain or amplification at the distal part of 17q is even more common, found in 40--70% of all MPNSTs ([Brekke et al., 2010](#mol22015961129-bib-0006){ref-type="ref"}; [Schmidt et al., 2000](#mol22015961129-bib-0045){ref-type="ref"}; [Yu et al., 2011](#mol22015961129-bib-0059){ref-type="ref"}).

Here, we aimed to identify clinically useful prognostic biomarkers, which may contribute to improved treatment design and outcome for MPNST patients, by performing genome‐wide RNA expression analysis followed by investigating up‐regulated genes at 17q that encode proteins representing putative treatment targets.

2. Material and methods {#mol22015961129-sec-sec2}
=======================

2.1. Patients and samples {#mol22015961129-sec-sec2.1}
-------------------------

Fresh frozen tumour tissue from eight neurofibromas and 30 MPNSTs (17 with NF1 and 13 with sporadic disease), and formalin‐fixed paraffin‐embedded (FFPE) tissue material from 63 MPNST patients (28 NF1 and 35 sporadic; 25 overlapping with the fresh frozen samples) was obtained from patients who were diagnosed during 1980--2002 at reference sarcoma centres at Skåne University Hospital, Lund, Sweden, and the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway ([Brekke et al., 2009](#mol22015961129-bib-0005){ref-type="ref"}) according to the guidelines given by the Scandinavian Sarcoma Group ([Nielsen et al., 2013](#mol22015961129-bib-0035){ref-type="ref"}). A part of the samples were also evaluated by the CHAMP study group of pathologists ([Mertens et al., 2000](#mol22015961129-bib-0032){ref-type="ref"}). Clinical data are summarized in [Table 1](#mol22015961129-tbl-0001){ref-type="table-wrap"}. The study was approved by the South‐Eastern Norway Regional Health Authority and the Regional Ethics Committee at Lund University according to national legislation.

###### 

Clinical characteristics of the MPNST patients.

  ------------------------------------------------------ ----------------- -----------------
                       Sample type:                        Fresh frozen          FFPA
                        Analysis:                         Gene expression     IHC on TMA
                   Number of patients:                          30                63
                                                                           
                       NF1/non‐NF1                             17/13             28/35
                    Median age (range)                      32 (14--79)       33 (13--85)
                   Gender (female/male)                        16/14             31/32
            Country of origin (Norway/Sweden)                  12/18             40/23
                Tumour grade (high/low/ND)                    23/4/3            50/8/5
         Complete surgical resection (yes/no/ND)              22/6/2            41/17/5
   Primary tumour site (extremities/non‐extremities/ND)      20/10/--           34/28/1
                Median tumour size (range)                 10 (4--25) cm     8 (2--40) cm
                 Follow up data available                       29                62
                  Median follow up time                   125 (±6) months   133 (±6) months
  ------------------------------------------------------ ----------------- -----------------

ND: no data.

2.2. RNA isolation {#mol22015961129-sec-sec2.2}
------------------

RNA was isolated from fresh frozen tissue samples by standard Trizol methodology. Samples were grinded in a mortar with liquid nitrogen and further dissolved and homogenized with a pellet pestle mortar in 1 ml Trizol (Invitrogen, Carlsbad, CA, USA), followed by phase separation by chloroform and precipitation using 2‐propanol. The RNA pellets were dissolved in RNase free water at 55 °C. The RNA concentration was measured by UV spectroscopy (NanoDrop 1000, Thermo Fisher Scientific, Waltham, MA, USA) and quality was determined by using the Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA). 32 of 38 samples had a RIN‐value of 7 or better. Three samples had RIN‐values 3--5, however these were still included based on the final evaluation of the quality parameters from the gene expression array data and the clustering of these samples with the other MPNST samples (see [Figure 1](#mol22015961129-fig-0001){ref-type="fig"}A).

![Three‐dimensional principal components plot based expression of the 1000 gene probes with highest variance across eight neurofibromas (blue spheres) and 30 MPNST samples (red) (A). \*Samples with RIN values between 3 and 5. Percentagewise distribution over 43 chromosome arms of Entrez annotated gene probes on the AB1700 microarray (N = 11,596 genes) (expected distribution; red bars) compared to the distribution of the significantly upregulated genes (N = 337) in MPNST vs neurofibroma (observed distribution; blue bars) (B). Statistical significance of the deviation between observed and expected distribution of the N = 337 upregulated genes in MPNST vs neurofibroma as sorted by the P‐value from a binomial distribution test, cumulative probability, P (X ≥ x) (C).](MOL2-9-1129-g001){#mol22015961129-fig-0001}

2.3. Gene expression analysis {#mol22015961129-sec-sec2.3}
-----------------------------

Gene expression analysis was performed using the Applied Biosystems 1700 microarray platform and the Human Genome Survey Microarray V2.0 containing 32,878 unique 60‐mer oligonucleotide probes (Applied Biosystems by Life Technologies, Foster City, CA). From each sample, 2 μg RNA was amplified, labelled and hybridized as described in the manufacturer\'s protocol. For the initial data analysis we used the ABarray software package (<http://bioconductor.org/packages/1.9/bioc/html/ABarray.html>) to run quality check and basic statistical analysis. Quantile normalized and log2 transformed expression data were used in our downstream statistical analysis. Flag values were replaced by using the Significance Analysis of Microarrays Excel Add‐in application (version 3.02; [http://www‐stat.stanford.edu/∼tibs/SAM/](http://www-stat.stanford.edu/%7Etibs/SAM/)) and the *k* nearest neighbours algorithm (k = 10). Probes with signal‐to‐noise ratios less than three in half of the samples and probes with flagged intensity values in more than 20% of the samples were removed, leaving us with a dataset containing measurements from 18,796 probes available at the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>, Series GSE66743). Gene expression intensity values were centred over the median value across all samples. We used the ABI Human Genome Survey Microarray Version 2 annotation file from GEO (platform GPL2986) for downstream analysis, and the 12,484 probes annotated by Entrez Gene ID\'s were included. SAM application and t‐test statistics with a two class unpaired response format were used to test for the significance of differentially expressed genes between defined groups. Principal component analysis was performed in Partek Genomics Suite 6.6 (Partek Inc., St. Louis, MO, USA). Gene set enrichment analyses were performed using the internet tools provided on the DAVID website ([Huang et al., 2009](#mol22015961129-bib-0015){ref-type="ref"}).

2.4. Immunohistochemistry {#mol22015961129-sec-sec2.4}
-------------------------

*In situ* protein expression analysis performed on 4 μm sections of the TMA was done according to the DAKO Envision protocol (DAKO, Glostrup, Denmark) as described ([Brekke et al., 2009](#mol22015961129-bib-0005){ref-type="ref"}), with the following adjustments: for the TOP2A antibody (NCL‐TOPOIIA, Novocastra, USA, 1:5 dilution), heat induced epitope retrieval was performed in a pressure cooker for 1 min at 120 °C in citrate buffer (pH 6.0) according to the manufacturer\'s recommendation; for the BIRC5 antibody (ab469, Abcam, Cambridge, UK, 1:400) and the TK1 antibody (ab57757, Abcam, 1:100) epitope retrieval was performed by heating in a microwave oven for 5 min at 850 W followed by 15 min at 100 W. Citrate buffer (pH 6·0) was used for BIRC5, and Tris--EDTA buffer (pH 9.0) was used for TK1.

The stained TMA sections were scanned at ×400 magnification using the Nano‐Zoomer Digital Pathology scanner (Hamamatsu Photonics K.K., Hamamatsu, Japan). Scoring was done by two of the authors independently (MK and MH) and quality controlled by a reference pathologist (BD). Nuclear and cytoplasmic staining was scored from 0 to 5 according to the distribution of positive cells (0 = 0%, 1 = \<1%, 2 = 1--10%, 3 = 11--33%, 4 = 34--66%, and 5 = 67--100%), and from 0 to 2 according to staining intensity (0 = negative, 1 = weak, and 2 = strong). The group sizes and survival properties for the patients in each of these staining categories were analysed individually, and two final categories were assigned before downstream analyses (see [Supplementary Figure 4](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}).

The target specificity of the antibodies was tested on Western blots as previously described ([Brekke et al., 2009](#mol22015961129-bib-0005){ref-type="ref"}) in two MPNST cell lines (ST88‐14 and STS26T) and a panel of cell lines from several other cancer types ([Supplementary Figure S1](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}). The MPNST cell lines were kindly provided by Dr. Nancy Ratner. The identity of the cell lines was validated by genotyping in our lab according to the protocol of the AmpFLSTR Identifiler PCR Amplification Kit (Applied Biosystems), and the genotypes are available upon request.

2.5. Statistical analysis {#mol22015961129-sec-sec2.5}
-------------------------

Comparison of gene expression among patients with high or low protein expression was done using Mann--Whitney *U* test. Disease‐specific survival curves were analysed using the Kaplan--Meier method and the Breslow test was used to compare the equality of the survival functions. For ordinal parameters with more than two categories, the *P*‐value for linear trend is presented. Finally, we used Cox proportional hazards regression modelling with Wald test to provide univariate and multivariate hazard‐ratios (HR) and confidence intervals (CI), and we defined distinct clinical subgroups of MPNST based on these results. All statistical analyses were performed using the SPSS software version PASW 18.0 (IBM Corporation, Armonk, NY, USA).

3. Results {#mol22015961129-sec-sec3}
==========

3.1. Differentially expressed genes in MPNST vs neurofibromas {#mol22015961129-sec-sec3.1}
-------------------------------------------------------------

Gene expression values were included for 12,484 probes in 30 MPNSTs and eight neurofibromas. The overall gene expression in the neurofibromas was clearly different from that in the majority of the MPNSTs ([Figure 1](#mol22015961129-fig-0001){ref-type="fig"}A). A two‐class unpaired SAM analysis of the gene expression profiles identified 437 of the 12,484 genes as down‐regulated in MPNST compared with neurofibromas, and 345 genes as up‐regulated, using a false discovery threshold of 1% (*Q* ≤ 0.01). The top 100 up‐ and down‐regulated genes are listed in [Supplementary Table S1A and S1B](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}, respectively.

Functional annotation clustering of the significantly differentially expressed genes between MPNST and neurofibromas showed the strongest enrichment of genesets containing cell cycle, cell division and kinetocore/chromosome‐condensation associated genes ([Supplementary Table S2A](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}). The most significantly enriched pathway genesets (KEGG pathways) included extracellular matrix (ECM)‐receptor interaction, complement/coagulation cascade, cell cycle, and DNA replication ([Supplementary Table S2B](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}).

Since MPNSTs typically have a high degree of DNA copy number alterations, we also investigated genesets according to the chromosomal distribution, and we found that up‐regulated genes in MPNST were overrepresented on chromosome arms 17q, 6p, 4q, and 9q, while they were underrepresented on 11q, 22q, 21q, and 11p ([Figure 1](#mol22015961129-fig-0001){ref-type="fig"}B). 17q was the region with the strongest enrichment of up‐regulated genes, harbouring 9.5% of these genes as compared to the expected 4.5% (Binominal distribution test, cumulative probability: P (X ≥ 9.5%) = 8·10^−^ ^5^ ([Figure 1](#mol22015961129-fig-0001){ref-type="fig"}C)). Among the 100 most up‐regulated genes, eight were encoded on 17q: *TOP2A* (rank 2), *BIRC5* (rank 3), *COL1A1* (rank 32), *NME1* (rank 64), *CACNA1G* (rank 66), *TK1* (rank 75), *CDC6* (rank 80), and *PRR11* (rank97) ([Supplementary Table S1A](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}). *BIRC5* and *TK1* are represented by two different probes on the AB1700 oligonucleotide array that recognize alternative transcript variants, where Probe\#1 represents the reference transcript in both cases.

We were not able to identify any significant differences in gene expression between MPNSTs from patients with NF1 and from non‐NF1 patients; all genes had a *Q*‐value above 0.25 (data not shown).

3.2. Clinical outcome by gene expression levels {#mol22015961129-sec-sec3.2}
-----------------------------------------------

In Kaplan‐Meyer analyses including 29 MPNST patients, five of the eight genes on chromosome arm 17q identified in the previous section, *BIRC5, CDC6, NME1, TK1*, and *TOP2A*, showed a significant association with disease outcome when the patients were dichotomized above or below median expression across all samples ([Supplementary Figure S2](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}). We also performed an unbiased genome wide Cox regression analysis for 10 years survival including 3340 genes on the AB1700 array that had a standard deviation across all MPNST samples of more than 1. The 43 genes that obtained an absolute *d*‐score ≥2 are listed in the [Supplementary Tables S3A and S3B](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}, in addition to the eight 17q genes identified in the previous section. The three genes *BIRC5, TK1*, and *TOP2A* were the only 17q genes that obtained a *Q‐*value below 0.25, and these were selected for further validation on the protein level.

3.3. Differential expression of proteins BIRC5, TK1, and TOP2A in MPNST tissue {#mol22015961129-sec-sec3.3}
------------------------------------------------------------------------------

Nuclear and cytoplasmic protein expression of BIRC5, TK1, and TOP2A was analysed by IHC on TMA sections containing tissue samples from 63 MPNSTs (representative samples are shown in [Figure 2](#mol22015961129-fig-0002){ref-type="fig"}). Grouping of tumour samples into two final categories with high and low staining is explained in section [3.4](#mol22015961129-sec-sec3.4){ref-type="sec"}. below.

![Representative MPNST tissue sections showing in situ IHC staining for BIRC5 (survivin), TK1, and TOP2A. Left column: negative staining, right column: positive staining. Enlarged insets are magnified 5×.](MOL2-9-1129-g002){#mol22015961129-fig-0002}

We analysed the association between gene expression and protein expression (Mann--Whitney *U* test) and found that samples with high levels of nuclear TOP2A and nuclear BIRC5 had significantly higher gene expression levels of the corresponding genes, while nuclear TK1 was weakly associated with *TK1* gene expression ([Supplementary Figure S3](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}). No significant associations were found between gene expression and cytoplasmic staining (data not shown). For this reason, and because nuclear staining is easier to score in a routine clinical setting, cytoplasmic staining was not included in subsequent analysis. The staining distribution and intensity scores for nuclear staining are summarized in [Supplementary Table S4](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}. There were no statistically significant differences in protein expression between tumours from NF1 and non‐NF1 patients for any of the three proteins.

3.4. Clinical outcome predicted by BIRC5, TK1, and TOP2A protein expression {#mol22015961129-sec-sec3.4}
---------------------------------------------------------------------------

For BIRC5 and TK1 both increasing number of positive nuclei (staining distribution) and increasing staining intensity were associated with worse prognosis, and two final IHC categories of tumour samples with high or low staining were defined by the sum of the distribution and intensity score ([Supplementary Figure S4A and B](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}). For TOP2A, only staining distribution was associated with prognosis, therefore the two final IHC categories were defined by the percentage of positive nuclei only ([Supplementary Figure S4C](#mol22015961129-sup-appsec1){ref-type="supplementary-material"}). High staining for BIRC5, TK1, and TOP2A showed significant association to poor disease‐specific survival in univariate Kaplan Meier and Cox regression analyses ([Figure 3](#mol22015961129-fig-0003){ref-type="fig"}, [Table 2](#mol22015961129-tbl-0002){ref-type="table-wrap"}). Multivariate Cox regression analysis showed that there was redundancy among the different proteins, as none of the individual proteins remained significant ([Table 2](#mol22015961129-tbl-0002){ref-type="table-wrap"}), although the overall Cox model of the three proteins was significant (P = 0.02). However, we found that when the patients were stratified by high or low nuclear staining of BIRC5, TOP2A added significant prognostic information to substratify the patients with low BIRC5, whereas TK1 added significant prognostic information to the patients with high BIRC5 expression in their tumours ([Figure 4](#mol22015961129-fig-0004){ref-type="fig"}A). Thus, the two combinations low BIRC5/low TOP2A and high BIRC5/low TK1 predicted good outcome, while the combinations low BIRC5/high TOP2A and high BIRC5/high TK1 predicted poor outcome (HR: 3.92; 95% CI: 1.79--8.57; [Table 3](#mol22015961129-tbl-0003){ref-type="table-wrap"}; [Figure 4](#mol22015961129-fig-0004){ref-type="fig"}B). This profile, referred to as an IHC risk profile, was independently significant when adjusted for patient age, gender, tumour size, site, grade, NF1‐status, and surgical remission (HR: 4.60; 95% CI: 1.47--14.4; [Table 3](#mol22015961129-tbl-0003){ref-type="table-wrap"}). Among the 35 patients with complete surgical resection, only 15% in the high risk group were alive two years after MPNST diagnosis, as compared to 78% in the low risk group. Even after ten years, 70% were still alive in the low risk group ([Figure 4](#mol22015961129-fig-0004){ref-type="fig"}C). All other combinations of the three proteins were also tested, but these combinations did not separate the patients into equally distinct prognostic groups.

![Association between BIRC5, TK1 and TOP2A protein expression and patient survival. The Kaplan Meier plots show disease‐specific survival as a function of high (red lines) and low (blue lines) IHC staining levels of nuclear BIRC5 (A), nuclear TK1 (B), nuclear TOP2A (C). P‐values for five‐year survival are shown (Breslow test).](MOL2-9-1129-g003){#mol22015961129-fig-0003}

###### 

Association between IHC score and five‐year MPNST specific survival.

                   Univariate   Multivariate                                                
  --------------- ------------ -------------- ------------- ------ ---- ------ ------------ ------
   Nuclear BIRC5                                                                            
      ‐ High           26           2.27       1.06--4.87    0.04   25   1.46   0.62--3.41   0.63
       ‐ Low           33           Ref                             31   Ref                
       ‐ ND            3                                                                    
    Nuclear TK1                                                                             
      ‐ High           15           2.44       1.11--5.36    0.03   15   2.08   0.90--4.81   0.09
       ‐ Low           42           Ref                             41   Ref                
     ‐ Missing         5                                                                    
   Nuclear TOP2A                                                                            
      ‐ High           17           2.20       1.001--4.85   0.05   17   1.82   0.79--4.23   0.16
       ‐ Low           40           Ref                             39   Ref                
     ‐ Missing         5                                                                    

n: number of cases; HR: hazard ratio; Ref: reference category; CI: confidence interval; ND: no data.

P‐value from Wald test.

Multivariate HR (all variables included in the Cox model).

![Stratification of MPNST patients based on the IHC risk profile defined by nuclear staining against BIRC5, TK1, and TOP2A, and comparison of survival curves for the high risk (red) and low risk (blue) groups (A). The Kaplan Meyer curves show disease‐specific survival for all MPNST patients (N = 56) (B) and MPNST patients with complete resection of tumour (N = 35) (C). P‐values for five‐year survival are shown (Breslow test).](MOL2-9-1129-g004){#mol22015961129-fig-0004}

###### 

Association between IHC risk profile and five‐year MPNST specific survival.

           Parameter            Univariate   Multivariate                                                 
  ---------------------------- ------------ -------------- ------------ -------- ---- ------ ------------ -------
       IHC risk profilec                                                                                  
          ‐ High risk               17           3.92       1.79--8.57   0.0006   12   4.60   1.47--14.4   0.009
           ‐ Low risk               39           Ref                              32   Ref                
              ‐ ND                  6                                                                     
           NF1 status                                                                                     
           ‐ Non‐NF1                34           Ref                              19   Ref                
             ‐ NF1                  28           0.98       0.48--2.02    0.96    25   2.49   0.71--8.74   0.15
             Gender                                                                                       
            ‐ Female                31           Ref                              20   Ref                
             ‐ Male                 31           0.72       0.35--1.48    0.37    24   0.94   0.31--2.81   0.91
   Completely resected tumour                                                                             
             ‐ Yes                  40           Ref                              30   Ref                
              ‐ No                  17           1.44       0.63--3.22    0.38    14   1.15   0.39--3.46   0.80
              ‐ ND                  5                                                                     
        Tumour location                                                                                   
         ‐ Extremities              34           Ref                              23   Ref                
       ‐ Non‐extremities            27           2.47       1.16--5.26    0.02    21   1.72   0.56--5.31   0.34
              ‐ ND                  1                                                                     
              Age                   62          1.008       0.99--1.03    0.34    44   0.99   0.95--1.03   0.65
          Tumour size                                                                                     
            ‐ ≤8 cm                 31           Ref                              25   Ref                
            ‐ \>8 cm                27           2.25       1.04--4.86    0.04    19   1.39   0.52--3.71   0.51
              ‐ ND                  4                                                                     
             Grade                                                                                        
             ‐ Low                  8            Ref                              6    Ref                
             ‐ High                 49           6.95       0.94--51.2    0.06    38    NC                 0.98
              ‐ ND                  5                                                                     

n: number of cases; HR: hazard ratio; Ref: reference category; CI: confidence interval; ND: no data; NC: nonconvergent.

P‐value from Wald test.

Multivariate HR (all variables included in the Cox model).

IHC high risk group: Positive BIRC5/Positive TK1 or Negative BIRC5/Positive TOP2A; IHC low risk group: Positive BIRC5/Negative TK1 or Negative BIRC5/Negative TOP2A.

For 24 patients with matching IHC and CNV data, the percentage of patients with copy number gain on chromosome arm 17q was slightly, but not significantly, higher in the high risk group as compared to the low risk group (86 vs 65%, *P* = 0.6).

4. Discussion and conclusions {#mol22015961129-sec-sec4}
=============================

4.1. Discussion {#mol22015961129-sec-sec4.1}
---------------

MPNSTs are highly aggressive neoplasms with no recommended treatment options beside surgery. In a recent review and meta‐analysis ([Kolberg et al., 2013](#mol22015961129-bib-0022){ref-type="ref"}), we found that the outcome from NF1‐associated MPNST has improved slightly over the last decades, whereas no improvement was seen for sporadic cases; the five‐year overall survival is now close to 50% for both patient groups. In order to improve MPNST outcome, biomarkers that identify high risk patients are needed, as well as novel drug targets in order to offer these patients targeted treatment. A handful of studies have described potential drug targets in MPNST ([Ghadimi et al., 2012](#mol22015961129-bib-0012){ref-type="ref"}; [Holtkamp et al., 2008](#mol22015961129-bib-0013){ref-type="ref"}; [Patel et al., 2012](#mol22015961129-bib-0039){ref-type="ref"}; [Peacock et al., 2013](#mol22015961129-bib-0040){ref-type="ref"}; [Wu et al., 2014](#mol22015961129-bib-0056){ref-type="ref"}; [Yang et al., 2011](#mol22015961129-bib-0058){ref-type="ref"}), but very few have been validated in independent series, and none has so far been implemented in clinical use.

The gene expression data presented in this study reveal many potential markers for MPNST beyond the 17q genes we have focused on here; some of them have been suggested by earlier studies. Miller and colleagues highlighted *CNP*, *PMP22*, and *NGFR* as down‐regulated, and *SOX9* and *TWIST1* as up‐regulated in MPNST as compared to benign Schwann cells ([Miller et al., 2006](#mol22015961129-bib-0033){ref-type="ref"}). These findings could be verified in our data, with the exception of *SOX9*, and *PMP22* was found among our top 100 down‐regulated hits. Levy and co‐workers found that Tenascin XB (*TNXB*) was down‐regulated in MPNST *vs* plexiform and dermal neurofibromas, while Tenascin C (*TNC*) was up‐regulated ([Levy et al., 2007](#mol22015961129-bib-0026){ref-type="ref"}). Our data confirm these findings, and interestingly *TNXB* was the 28th gene on our top 100 down‐regulated list. *TNC* was also identified as up‐regulated in MPNST by Karube and colleagues ([Karube et al., 2006](#mol22015961129-bib-0016){ref-type="ref"}), along with keratin 18 (*KRT18*), survivin (*BIRC5*), and the collagen VIa3 (*COL6A3*), while *IGFBP6* was reported to be down‐regulated, all these findings are in agreement with our data and *IGFBP6* was even found on our top 100 down‐regulated list. In a recent study, *AURKA* was identified as overexpressed in MPNST ([Patel et al., 2012](#mol22015961129-bib-0039){ref-type="ref"}), and a moderate overexpression was also seen in our samples. *EGFR* has been found to be up‐regulated in MPNST in several previous studies ([Holtkamp et al., 2008](#mol22015961129-bib-0013){ref-type="ref"}; [Rahrmann et al., 2014](#mol22015961129-bib-0041){ref-type="ref"}; [Tabone‐Eglinger et al., 2008](#mol22015961129-bib-0052){ref-type="ref"}), but this was not confirmed in our samples. However, a high percentage of MPNSTs have previously been shown to lack expression of EGFR ([Watson et al., 2004](#mol22015961129-bib-0055){ref-type="ref"}), and it is possible that EGFR is important for tumourigenesis in only a subset of these tumours, supported by the finding that only about 35% of MPNSTs have increased gene dosage of EGFR ([Brekke et al., 2010](#mol22015961129-bib-0006){ref-type="ref"}; [Du et al., 2013](#mol22015961129-bib-0010){ref-type="ref"}; [Holtkamp et al., 2008](#mol22015961129-bib-0013){ref-type="ref"}), therefore we need a higher number of tumour samples than included in the present study to determine the role of EGFR in MPNSTs. On our top 100 list of up‐regulated genes in MPNST only one gene has a higher ranking than *BIRC5* and *TOP2A*, *KIAA0101*, the importance of this gene is not further validated in this study, and to our knowledge it has not been described in MPNST previously. However, *KIAA0101* has been identified as upregulated and a potential prognostic marker in several studies on other cancer types ([Xie et al., 2014](#mol22015961129-bib-0057){ref-type="ref"}), and might also prove to be important in tumorigenesis of MPNST in the future.

From the current transcriptome data we found that chromosome arm 17q has the highest relative amount of up‐regulated genes, and several of these genes carried prognostic information. We have previously found that chromosome arm 17q was one of the most frequently gained genomic regions in MPNST ([Brekke et al., 2010](#mol22015961129-bib-0006){ref-type="ref"}; [Lothe et al., 1996](#mol22015961129-bib-0028){ref-type="ref"}), and we and others have suggested that increased tumour mRNA levels of the two genes *TOP2A* and *BIRC5* have the potential to be markers for poor prognosis in MPNST ([Ghadimi et al., 2012](#mol22015961129-bib-0012){ref-type="ref"}; [Karube et al., 2006](#mol22015961129-bib-0016){ref-type="ref"}; [Kresse et al., 2008](#mol22015961129-bib-0023){ref-type="ref"}; [Levy et al., 2004](#mol22015961129-bib-0027){ref-type="ref"}; [Peacock et al., 2013](#mol22015961129-bib-0040){ref-type="ref"}; [Skotheim et al., 2003](#mol22015961129-bib-0049){ref-type="ref"}; [Storlazzi et al., 2006](#mol22015961129-bib-0051){ref-type="ref"}). A high level of TOP2A protein has also been shown to be associated with poor outcome ([Skotheim et al., 2003](#mol22015961129-bib-0049){ref-type="ref"}). Although prognostic gene expression profiles and PCR based tests have been suggested for many cancers, very few have found their way into clinical practice. We therefore aimed to develop an IHC test that can immediately be used in routine labs.

Nuclear staining is best suited for reproducible visual scoring, and we identified a prognostic profile defined by nuclear expression of the three 17q encoded proteins BIRC5, TOP2A and TK1, all of which are also potential drug targets. Topoisomerases are essential components of the DNA replication machinery where they are responsible for controlling and altering the topology of the DNA. Clinical trials with etoposide for MPNST have shown promising results ([Kinebuchi et al., 2005](#mol22015961129-bib-0019){ref-type="ref"}; [Steins et al., 2002](#mol22015961129-bib-0050){ref-type="ref"}), and primary data collection for a phase II study using this drug in combination with ifosfamide, doxorubicin, and radiation therapy was recently completed, but the final results are still pending ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); NCT00304083). Single agent topoisomerase inhibitors are unlikely to have a strong effect on survival, given the experience from use of these drugs in soft‐tissue sarcomas including MPNST for decades. However, therapy using TK1 or BIRC5 inhibitors in treatment of MPNST has not been explored to our knowledge, and combination therapy including such inhibitors might prove successful.

The antiapoptotic protein BIRC5, also known as survivin, has previously been proposed as a potential drug target in MPNST ([Karube et al., 2006](#mol22015961129-bib-0016){ref-type="ref"}), and a series of strategies directed against BIRC5 are currently in clinical trials in other cancer types, including antisense oligonucleotides, immunotherapy, and small molecule inhibitors ([Ryan et al., 2009](#mol22015961129-bib-0043){ref-type="ref"}; [Sioud et al., 2013](#mol22015961129-bib-0048){ref-type="ref"}). In addition, MPNST cell lines treated with the survivin inhibitor sepantronium bromide (YM155) showed reduced proliferation ([Ghadimi et al., 2012](#mol22015961129-bib-0012){ref-type="ref"}). In support of our finding, a recent study found that high mRNA levels of *BIRC5* was associated with poor outcome in paediatric MPNST ([Alaggio et al., 2013](#mol22015961129-bib-0001){ref-type="ref"}). It should be noted that in one previous study, high levels of BIRC5 were also observed in benign tumours of the peripheral nervous system, schwannomas and neurofibromas ([Sasaki et al., 2002](#mol22015961129-bib-0044){ref-type="ref"}), in contrast to our results.

For some time, viral TK1 has served as a target in treatment of a number of virus‐induced diseases using drugs such as zidovudine (AZT), acyclovir, and ganciclovir. TK1‐directed treatment has proven so effective that attempts have also been made to introduce viral TK1 into cancer cells by gene therapy followed by exposure to the antiviral drugs ([Oliveira et al., 2012](#mol22015961129-bib-0037){ref-type="ref"}; [Packer et al., 2000](#mol22015961129-bib-0038){ref-type="ref"}). TK1 is also an important activator of the prodrug intermediate 5\'‐fluorodeoxyuridine (5‐FdU) to the cytotoxic 5\'‐fluorodeoxyuridine monophosphate (5‐FdUMP), which is a suicide substrate for thymidylate synthetase (TYMS). A high serum level of TK1 has been demonstrated to be a marker of poor prognosis for several cancers ([Aufderklamm et al., 2012](#mol22015961129-bib-0002){ref-type="ref"}), including breast cancer, colorectal cancer, lung cancer, and non‐Hodgkin lymphoma. The finding of high levels of TK1 in MPNSTs from patients with poor prognosis suggests that drugs directed towards TK1, or that are activated by TK1, may be useful for treatment of these patients.

4.2. Conclusions {#mol22015961129-sec-sec4.2}
----------------

In this study, we identified three molecular markers, BIRC5, TK1 and TOP2A that significantly stratify patients into a good and poor prognostic group both on the mRNA and protein level. Furthermore, as BIRC5, TK1 and TOP2A are drug targets, future clinical trials for MPNST patients could be designed to explore the benefit of targeting these markers using their combined protein expression to predict treatment response.
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Supplementary Figure S1 Validation of antibodies. The specificity of each antibody was tested by Western blots of protein extracts from different cancer cell lines, including two MPNST cell lines (left lanes). β‐Actin was used as positive control (Antibody A5316 Sigma--Aldrich, St. Louis, MO, USA).
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Click here for additional data file.
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Supplementary Figure S2 Association between gene expression and survival for five genes encoded on chromosomal arm 17q. The Kaplan Meier plots show disease‐specific survival for MPNST patients as a function of gene expression levels above (red lines) or below (blue lines) the median for BIRC5 (A), CDC6 (B), NME1 (C), PRR11 (D), TK1 (E), and TOP2A (F). BIRC5 and TK1 are represented by two different oligonucleotide probes, indicated by solid lines Probe\#1 and dashed lines for Probe\#2. P‐values for five‐year survival are shown (Breslow test).
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Supplementary Figure S3 Correlation between gene expression and protein expression. Comparison of the IHC staining for TOP2A (A), BIRC5 (B), and TK1 (C) expression levels of the corresponding genes. For BIRC5 and TK1, two different oligonucleotide probes were present on the gene expression array (Probe\#1 in blue, Probe\#2 in green). P‐values from Mann--Whitney U test.
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Supplementary Figure S4 The Kaplan Meier plots show disease‐specific survival as a function of distribution score (A, B, C) and intensity score (D, E, F), as well as combined score (sum of the above) (G,H,I) for the three proteins BIRC5, TK1 and TOP2A, respectively. The red and blue arrows indicate dichotomizing of tumour samples into two final IHC categories with high and low staining. For BIRC5 combined score: low = 0--2, high = 3--6; for TK combined score: low = 0--3, high = 4--6, for TOP2A distribution score: low = 0--2, high = 3--5.
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Supplementary Figure S5 Association between cytoplasmic BIRC5, TK1 and TOP2A protein expression and patient survival. The Kaplan Meier plots show disease‐specific survival as a function of high (red lines) and low (blue lines) IHC staining levels. P‐values for five‐year survival are shown (Breslow test).
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